Brian Del Buono
Vice President, Stuart Therapeutics
Production and Use of Collagen Mimetic Peptides for Therapeutic and Diagnostic Applications
Stuart Therapeutics (formerly known as Sustain Scientific) has developed a technology that offers an innovative approach to targeting and delivery of a variety of therapeutic and diagnostic agents. This technology builds upon proprietary structures for collagen mimetic peptides (CMPs), which not only mimic human collagen in its structure, chemistry and behavior, but which also have been shown to intrinsically promote tissue healing, speeding the healing process. Importantly, the CMPs also can deliver small and large molecule therapeutics, biologics and diagnostic agents in a targeted fashion. Using Stuart Therapeutics’ CMP-based approach, the bioavailability of linked drugs and/or biologics can be modulated, creating numerous possibilities for targeted and sustained/timed delivery of medications, at more precise and effective dosages, to a specific area of damage or disease condition, potentially reducing the magnitude of the clinical problem of poor patient compliance in medication administration. The flexibility of Stuart Therapeutics’ CMP-based technology thus offers a new and unique way to control the dosing, efficacy, and potentially the adverse side effects of many therapeutic and diagnostic agents already in use, and to improve the prospects of emerging therapeutic and diagnostic compounds. Stuart Therapeutics is exploring the use of this technology in the treatment and diagnosis of a variety of human and animal diseases and disorders, including those afflicting the eye, skin, and other organs and organ systems, as well as certain types of cancers.
Dr. Del Buono has over 30 years of multinational R&D, legal and regulatory experience in technology development and licensing, with an emphasis on both branded and generic pharmaceuticals, biologics and medical devices. He has worked extensively in intellectual property, regulatory affairs, strategic business development, mergers and acquisitions and technology licensing. He also has substantial experience in biotech/pharma R&D innovation and management, and has had key responsibilities in large merger integration efforts. Prior to joining Sustain Dr. Del Buono was Sr. VP, Chief Legal Officer & Corporate Secretary for The Sun Products Corporation, was a partner at a Washington, DC intellectual property law firm, and was manager of New Products Development for a division of Becton Dickinson. He holds a Ph.D. in Microbiology/Biochemistry from The Pennsylvania State University and a J.D., cum laude, from Georgetown University Law Center, and was a postdoctoral fellow in Biochemistry and Hematology/Oncology at Boston University School of Medicine.